Current pharmacotherapy of overactive bladder

Detalhes bibliográficos
Autor(a) principal: Kreydin,Evgenyi I.
Data de Publicação: 2021
Outros Autores: Gomes,Cristiano M., Cruz,Francisco
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000601091
Resumo: ABSTRACT Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.
id SBU-1_f5649cebfbb3cae149739b5d8d92c307
oai_identifier_str oai:scielo:S1677-55382021000601091
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Current pharmacotherapy of overactive bladderUrinary Bladder, OveractiveDrug TherapyMuscarinic AntagonistsUrinary IncontinenceABSTRACT Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.Sociedade Brasileira de Urologia2021-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000601091International braz j urol v.47 n.6 2021reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2021.99.12info:eu-repo/semantics/openAccessKreydin,Evgenyi I.Gomes,Cristiano M.Cruz,Franciscoeng2021-09-29T00:00:00Zoai:scielo:S1677-55382021000601091Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2021-09-29T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Current pharmacotherapy of overactive bladder
title Current pharmacotherapy of overactive bladder
spellingShingle Current pharmacotherapy of overactive bladder
Kreydin,Evgenyi I.
Urinary Bladder, Overactive
Drug Therapy
Muscarinic Antagonists
Urinary Incontinence
title_short Current pharmacotherapy of overactive bladder
title_full Current pharmacotherapy of overactive bladder
title_fullStr Current pharmacotherapy of overactive bladder
title_full_unstemmed Current pharmacotherapy of overactive bladder
title_sort Current pharmacotherapy of overactive bladder
author Kreydin,Evgenyi I.
author_facet Kreydin,Evgenyi I.
Gomes,Cristiano M.
Cruz,Francisco
author_role author
author2 Gomes,Cristiano M.
Cruz,Francisco
author2_role author
author
dc.contributor.author.fl_str_mv Kreydin,Evgenyi I.
Gomes,Cristiano M.
Cruz,Francisco
dc.subject.por.fl_str_mv Urinary Bladder, Overactive
Drug Therapy
Muscarinic Antagonists
Urinary Incontinence
topic Urinary Bladder, Overactive
Drug Therapy
Muscarinic Antagonists
Urinary Incontinence
description ABSTRACT Overactive bladder is a symptom complex consisting of bothersome storage urinary symptoms that is highly prevalent among both sexes and has a significant impact on quality of life. Various antimuscarinic agents and the beta-3 agonists mirabegron and vibegron are currently available for the treatment of OAB. Each drug has specific pharmacologic properties, dosing schedule and tolerability profile, making it essential to individualize the medical treatment for the patient's characteristics and expectations. In this manuscript, we review the most important factors involved in the contemporary pharmacological treatment of OAB.
publishDate 2021
dc.date.none.fl_str_mv 2021-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000601091
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382021000601091
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1677-5538.ibju.2021.99.12
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.47 n.6 2021
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318078133010432

Registros relacionados